Trevena, Inc. (TRVN) Company Profile
Trevena Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250. Its TRV130 is a Mu-receptor G protein Pathway Selective (Mu-GPS) modulator that activates G protein. Its TRV250 is a small molecule G protein biased ligand of the d-opioid receptor in preclinical development. Its TRV734 is a small molecule Mu-GPS that it has discovered and has developed through Phase I as a first-line, orally administered compound for the treatment of moderate to severe acute and chronic pain. Its TRV027 is a peptide b-arrestin biased ligand that targets the angiotensin II type 1 receptor (AT1R). In addition to these three product candidates, the Company has identified and has completed the Phase I program for TRV734.
News about TRVN
GrafTech Is Repurchasing Stock After Making Restructuring Efforts
With Brookfield Asset Management Inc. (NYSE:BAM) selling 20 million shares of GrafTech International (NYSE:EAF), investors may believe that the shares are overvalued. However, research on the graphite electrode products shows that the stock returns c...Read More>>>
Trevena Inc (TRVN) Expected to Post Earnings of -$0.19 Per Share
Wall Street analysts expect Trevena Inc (NASDAQ:TRVN) to post ($0.19) earnings per share for the current quarter, according to Zacks. Zero analysts have made estimates for Trevena’s earnings. The highest EPS estimate is ($0.18) and the lowest i...Read More>>>
Microsoft: Low Downside Risk, But Potential For Innovation-Driven Upside With Cloud And GitHub
Even as Microsoft's (MSFT) stock has been flat or down this month since the GitHub acquisition, I believe in the long-term GitHub has significant chances in boosting a variety of Microsoft software and Internet services segments, even outside of clou...Read More>>>
Somewhat Positive Press Coverage Somewhat Unlikely to Impact Trevena (TRVN) Share Price
Media stories about Trevena (NASDAQ:TRVN) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than twenty million news and blog sources in r...Read More>>>
What I Learned About Bitcoin Could Make You A Fortune...
When I was first asked to write a book about bitcoin, the price was hovering at about $3,000. As part of my research, I bought a little. By the time the book was finished, which was really only a matter of weeks, the price had risen to just a tad ove...Read More>>>